Chan "credible evidence in the case, and there will be a clear advantage, and it is the management of infection and spread of Ebola virus flare will then be changed," he said at a press conference,.
It is expected to be published later on Friday, Mark and NewLink Genetics was developed by the Ebola virus from the vaccine trial known as VSV-EBOV information.